These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35994853)

  • 1. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
    Kumar V; Kumar S; Sharma PC
    Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus vaccine development: from SARS and MERS to COVID-19.
    Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current advances in the development of SARS-CoV-2 vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.
    Mukherjee S; Ray SK
    Infect Disord Drug Targets; 2022; 22(4):e080222200919. PubMed ID: 35135456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of developing a protective peptide-based vaccines against SARS-CoV-2.
    Shalash AO; Toth I; Skwarczynski M
    Drug Dev Res; 2022 Sep; 83(6):1251-1256. PubMed ID: 35751566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
    Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
    Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms.
    Aileni M; Rohela GK; Jogam P; Soujanya S; Zhang B
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.